IMV Inc.


IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV develops T cell-activating cancer immunotherapies and other vaccine candidates based on DepoVax™, the company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. IMV has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The company is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. IMV also has ongoing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus.

streetwise book logo Streetwise Company Fact Sheet

2024/5/27 11:46:22


Streetwise Reports Articles

12/27/2022 - View Article
11/29/2022 - View Article